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Abstract
Schizophrenia is a chronic and severe mental disorder that affects over 20 million people worldwide. Common symptoms
include distortions in thinking, perception, emotions, language, and self awareness. Different hypotheses have been proposed to
explain the development of schizophrenia, however, there are no unifying features between the proposed hypotheses.
Schizophrenic patients have perturbed levels of glucose in their cerebrospinal fluid, indicating a disturbance in glucose
metabolism. We have explored the possibility that disturbances in glucose metabolism can be a general mechanism for
predisposition and manifestation of the disease. We discuss glucose metabolism as a network of signaling pathways. Glucose
and glucose metabolites can have diverse actions as signaling molecules, such as regulation of transcription factors, hormone and
cytokine secretion and activation of neuronal cells, such as microglia. The presented model challenges well-established concepts
in enzyme kinetics and glucose metabolism. We have developed a ‘two-cell’ model of glucose metabolism, which can explain
the effects of electroconvulsive therapy and the beneficial and side effects of olanzapine treatment. Arrangement of glycolytic
enzymes into metabolic signaling complexes within the ‘two hit’ hypothesis, allows schizophrenia to be formulated in two steps.
The ‘first hit’ is the dysregulation of the glucose signaling pathway. This dysregulation of glucose metabolism primes the central
nervous system for a pathological response to a ‘second hit’ via the astrocytic glycogenolysis signaling pathway.
Introduction
The phenotypic complexity and multifarious nature of so-
called ‘schizophrenic psychoses’ have prevented a simple,
biologically based hypothesis for schizophrenia [1]. The ‘two
hit’ hypothesis of schizophrenia suggested back in 2001 by
Maynard et al., implied that dysregulation of cell–cell sig-
naling by a ‘first hit’, primes the central nervous system. The
‘second hit’, an environmental insult, promotes a patholo-
gical response via the same signaling pathway [2, 3]. Inter-
estingly, environmental insults are common tools used in
animal models of fear conditioning or aversive training [4].
Recently, Rowland et al. demonstrated increased L-
lactate (L-lac−) levels in the brain during acute psychosis
[5]. However, they interpreted their novel data using the
didactic concept of glucose metabolism that dominates
many scientific hypotheses. They assumed that anaerobic
glycolysis and mitochondrial dysfunction were the source
of the increased L-lac− levels. Here, we integrate the data
of Rowland et al. on the basis of the ‘two hit’ hypothesis.
To formulate our hypothesis, we have taken inspiration
from Mae Wan-Ho’s voyage of discovery through different
areas of contemporary physics, including non-equilibrium
thermodynamics, quantum optics, and fractals [6]. We have
zoomed in on her sub-cellular map to rearrange the well-
established concept of glucose metabolism into a concept of
dynamic cell–cell signaling. In the first part of our model, we
softly tread the path of glucose in the brain. The second part
of our model is much rougher, akin to white water rafting
and integrates the dual flow of streams of monocarboxylates.
An alternative view of glucose metabolism
As scientists, more than a few times in life, we have learnt
the pathway of glucose metabolism by rota. But, have the
concepts that you have learned changed over the past few
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decades? When considering this question, bear in mind, that
approximately every 9 years the amount of scientific pub-
lications double and that glucose metabolism is a scientific
field [7]. Also consider that ‘Medizinische Biochemie’
published by Rapoport in 1962 [8] consisted of 992 pages,
divided into four sections. Alone, the section dealing with
the intermediate metabolism of carbohydrates, lipids, ster-
oids, amino acids and proteins, nucleic acids and porphyrin
and haem compounds totaled 336 pages [9]. If we apply the
same rationale, the section relating to glucose metabolism
must now be worth an extraordinary number of pages,
unless nothing has changed in the past 60 years in biology.
The belief that nothing has changed and nature has kindly
sorted the glycolytic enzymes by the gradual degradation of
the carbon backbone can help us to learn the names of the
enzymes, products, and substrates. However, it is also one
way to avoid the new data presented in this exponential
increase in publications. Consider the enzyme, glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). A litera-
ture search for “GAPDH” and “review” alone generates
over 100,000 hits. In biology, glycolysis is known to par-
ticipate in DNA repair and transcription factor regulation
[10], mitochondrial membrane permeability, and apoptosis
[11]. Glycolysis is also an on-board engine driving vesicles
a distance of up to 1 m [12]. Therefore, simply defining
glycolysis as a cytoplasmic process of randomly distributed
enzymes providing two molecules of pyruvate and two
molecules of NADH-H+ is just a man-given definition.
Accordingly, it is a matter of definition whether one con-
siders GAPDH as a multifunctional protein with functions
distinct from glycolysis, or whether all functions performed
by GAPDH relate to glycolysis [13].
One of the consequences of this flood of information is
that scientists tend to specialize in small and distinct scientific
fields. Fatally, this leads to the repetition of the didactically
based concept of glucose metabolism in all scientific manu-
scripts. As a consequence, the didactic sorting of glycolytic
enzymes has changed into a scientific ‘fact’. We are not only
questioning the ‘fact’ but also provide an alternative model;
glucose-metabolizing enzymes sorted by energy transfer.
Depending on the textbook, GAPDH forms NADH-H+,
which diffuses as NADH to the mitochondria to be recov-
ered. Alternatively, more complicated cytosolic metabolic
steps can be introduced. For example, in the textbook of
Rapoport from 1987, GAPDH is functionally linked with
lactate dehydrogenase (LDH) [14]. Yet in scientific manu-
scripts, it depends on the topic whether the GAPDH•LDH
complex [15, 16], LDH, and L-lac− exist [17]. In modern
didactic biology, LDH does not exist because LDH is only
introduced when obligate aerobic organisms start to ferment
glucose to lactic acid (L-lacH). A similar process is well
known for facultative aerobic yeast fermenting glucose to
ethanol. Logically, as the scientific field of glucose
metabolism grows exponentially, the didactically based
concept of glucose metabolism must decline.
Learning is like rowing against the current. As soon as
you stop, you drift backwards. The well-established concept
of glucose metabolism starts by learning names of a dozen
enzymes arranged by the graded degradation of the carbon
backbone. It ends by drawing a circle around these enzymes
and naming it the blueprint of life. However, this blueprint
of life is a flowchart in a circle and akin to the fairy tale,
‘The Emperor’s New Clothes’. Scientists have been rowing
the current concept of glucose metabolism up-stream for
centuries. Here we test the hypothesis that learning is like
floating the path scientists have rowed. Our floating tour
takes us down the ‘glucose creek’ in the brain. Here, when
neurons fire and consume fuel, the reverberatory current is
the flow of glucose and glucose metabolites. These rever-
beratory currents induce lasting cellular changes that add to
the stability of the current [18]. Put simply, synapses with
high-energy turnover stabilize themselves. Growing evi-
dence suggests that the disease group ‘schizophrenic psy-
chosis’ is linked to turbulences in this ‘glucose creek’ [5].
Let us assume the fuel of neurons is a mixture of L-lacH,
pyruvic acid (pyrH), and glucose. This turns glucose
metabolism into a signaling pathway, because L-lac− and
pyruvate (pyr−) directly interact with the cellular NAD+/
NADH-H+ ratio. Glucose metabolism is highly dynamic
and monocarboxylates, such as pyr− and L-lac− are per-
manently and simultaneously imported and exported by the
same cell. This dynamic sending (export) and receiving
(import) of monocarboxylates modulates pH- and redox-
sensitive signaling pathways [19]. An imbalance in the
NAD+/NADH ratio is associated with schizophrenia [20]
and the activity of the risk gene, catechol-O-methyl-
transferase depends on the redox status of the cystine group
[21]. It is well established that glucose itself directly triggers
the release of insulin from pancreatic β-cells [22]. Conse-
quently, glucose metabolism is a signaling pathway and
glucose and glucose metabolites are signaling molecules.
Furthermore, glycogen granules represent storage vesicles
of the signaling molecules, glucose-1-phosphate and glu-
cose. Importantly, memory formation is functionally linked
to astrocytic glycogenolysis [4]. In astrocytes, muscle cells
and thrombocytes the catabolic breakdown of glycogen is
the preferred route of metabolism. The central position of
astrocytic glycogenolysis in memory formation suggests
that the signal encoding memory formation is encoded in
the change of the L-lac−/pyr− ratio.
Following the ‘sweet’ signal
Our suggested route down the ‘glucose creek’ of the brain is
not present in commonly used brain architecture maps
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(Fig. 1). Consider the glucose concentrations in the brain. In
1980, Gjedden et al. revealed that the concentration of
glucose in brain interstitial fluid (ISF) is low (2.6 mM) [23].
More recent data showing that ISF and cerebrospinal fluid
are permanently exchanged, support this [24]. The low
glucose concentration of the ISF strongly suggests that
neurons do not acquire their glucose from the ISF. Instead,
astrocytes must provide neurons with glucose and that
microglial cells are kept ‘arrested’ in low glucose. Micro-
scopic data demonstrate that blood capillaries (5.5 mM,
glucose) are covered by astrocytes, meaning neurons do not
have direct access to blood vessels [25]. Furthermore,
neurons themselves are not completely covered by astro-
cytes. Thus astrocytes, through direct and specific contacts
with neurons, act as pipeline of glucose to neuronal com-
partments of high-energy demand [26].
The first glucose transporter (GLUT) was cloned in 1985
[27]. This discovery places GLUTs, rather than hexokinase
II as the first regulatory enzyme of glycolysis. As such, our
tour down the ‘glucose creek’ means we encounter the first
enzyme of glucose metabolism three times. In the context of
schizophrenia, the critical passage is the astrocyte-neuron
compartment and it is stabilization of astrocyte-neuron
compartments that is key. It is obvious, that cell-adhesion
proteins must also play a key role in glucose flow [28].
Mechanisms stabilizing the cell–cell compartment, such as
mechanisms that accelerate glucose flow are directly
involved in regulating the stability of the astrocyte-neuron
compartment [29]. Mechanisms that detect an incompletely
sealed compartment and mechanisms involved in pruning,
brain plasticity, and brain development are also involved in
regulating the stability of astrocyte-neuron compartments
[29]. Interestingly, many of the listed risk genes and bio-
marker candidates of schizophrenia are functionally and
directly connected to the dynamics of this cell-to-cell pas-
sage of glucose [1].
Fig. 1 Hypothetical flow of glucose in the brain. The concentration
of glucose in the interstitial fluid is low (2.6 mM) [23] and insufficient
to supply neuronal compartments of high-energy demand. Astrocytic
endfeet completely cover capillaries, where the concentration of glu-
cose is high (5.5 mM) [25]. Glucose is transported via glucose trans-
porters (GLUTs) from the blood stream, across the astrocyte and
delivered to neuronal compartments of high-energy demand via
astrocytic and neuronal GLUTs. Astrocytic glycogenolysis is a sig-
naling pathway producing glucose, which enters the glucose transit
pathway and glucose-1-phosphate. The latter is converted to glucose-
6-phosphate, which inhibits hexokinase II [73], thereby blocking
astrocytic glycolysis. Decreased astrocytic glycolysis further increases
the availability of glucose for neuronal transit. A ‘tightly’ regulated
astrocyte-neuron compartment ensures delivery of glucose to the
neuron and keep microglial cells in a ‘quiescent’ state. In contrast, a
‘compromised’ astrocyte-neuron compartment, perhaps due to the
altered expression of stabilizing genes, genetic variations, or epige-
netic modifications, may lead to glucose ‘leakage’, promoting for-
mation of a glucose gradient and subsequent microglial activation.
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Memory consolidation is functionally coupled to the
upregulation of mRNA for proton-linked monocarboxylate
transporter 1 (MCT1), muscle LDH (LDH-m), and heart
LDH (LDH-h), astrocytic and neuronal GLUTs and astro-
cytic proton-linked MCT4 [30]. Only the neuronal proton-
linked MCT2 remains unchanged [30]. Thus, as a key
regulator of glucose flow, the upregulation of neuronal and
astrocytic GLUTs causes the ‘glucose creek’ to switch from
a trickle to a torrent.
If we understand schizophrenia as an imbalance in glu-
cose metabolism and glucose metabolism is the signaling
pathway that dynamically regulates the stability of the
astrocyte-neuron compartment. Then it is rational to suggest
that an imbalance in glucose metabolism can be linked to
dysregulated astrocyte-neuron compartments. A dysregu-
lated astrocyte-neuron compartment can leak the signaling
molecule glucose, into the ISF and activate surrounding
microglial cells. Glucose-activated microglial cells upregu-
late inflammatory proteins and increase phagocytosis and
tumor necrosis factor-alpha secretion [31]. Interestingly,
glucose deprivation sensitizes microglia, promoting the
release of inflammatory mediators, and primes microglial
function [31]. As discussed by Stöber and co-workers, the
release of other biomarker candidates, such as interleukin-
1β (IL-1β), IL-6 and brain-derived neurotrophic factor are
also directly triggered by glucose or its metabolites [1, 32].
The direct action of glucose and glucose metabolites in
regulating cell homeostasis sets glucose metabolism as the
‘major in command’ or as the ‘operating system’ of cells.
Thus, the ‘chicken-egg dilemma’ in schizophrenia can be
reduced to imbalance in glucose metabolism [33].
The tour down ‘glucose creek’ is too short to take in
other details. Data, such as the histology showing reduced
numbers of neutrophils, the steroid-dependent regulation of
cell-adhesion proteins in context of pruning and schizo-
phrenia, the glutamate-glutamine cycle and the naming and
functional integration of further ‘risk’ genes, would surely
further support our hypothesis [1]. It would also prevent us
from reaching the end of our tour, which concludes with the
fact that glucose levels are significantly increased in the
cerebrospinal fluid of ‘drug naïve’ schizophrenics [34].
The two-way flow of monocarboxylic acids
The opening of a bottle of champagne releases a force
powerful enough to propel the cork to the ceiling and
beyond, a bit like releasing a mysterious Djinn. If a multi-
cellular organism channels such a force (or flow of energy)
via a theoretical monocarboxylic acid•carbonic acid
exchanger, then oxidative phosphorylation would be cou-
pled to the uptake of its substrate, L-lacH from the envir-
onment [35]. In fact, this theoretical monocarboxylic
acid•carbonic acid exchanger exists in the form of the
proton-linked MCT1•carbonic anhydrase II (CAII) complex
[36].
The well-established flowchart of glycolytic enzymes is
in fact a riddle; one molecule of glucose (C6H12O6) is
metabolized to two molecules L-lac− (C3H5O3
−). This is in
contrast to the work of Meyerhof, which determined that
one molecule of glucose is metabolized to two molecules of
L-lacH (C3H6O3) [37]. So, the riddle is, ‘Where have the
two protons (H+) gone?’. The answer to this conundrum
must be that one of the well-established glycolytic reactions
is incorrect and that one of the intermediate products of the
glycolytic pathway must be an organic acid. If this con-
tinuously formed acid is located in the immediate proximity
of a proton-linked MCT, a pH gradient (or flow of energy)
will be created. This flow of energy will be sufficient to
unidirectionally drive the export of monocarboxylic acids
(Fig. 2). Importantly this export would be independent from
the pH and monocarboxylate concentration of the cytosol
and environment. It would, however, depend on glycolytic
flow. A proton-linked MCT4•phosphoglycerate kinase
(PGK) complex would be perfectly placed to fulfill this task
[35]. Unexported monocarboxylic acids would not only
increase cytosolic monocarboxylate, they would also gen-
erate an additional signal in the form of a proton. This
proton would be detected by pH-dependent metabolic
adenylyl cyclase and directly couple the glycolysis rate to
cAMP-dependent signaling pathways [38]. We would then
have a situation where the proton-linked MCT1•CAII uni-
directionally imports monocarboxylic acids at the same time
in the same cell, as the proton-linked MCT4•PGK complex
unidirectionally exports monocarboxylic acids [39]. In this
situation, the well-established concept of enzyme kinetics,
based on reversibly acting enzymes collapses.
The didactic concept of glucose metabolism inveigles us
to consider proton-linked MCTs as L-lac− transporters.
However, proton-linked MCTs actually catalyze the mem-
brane exchange of monocarboxylic acids (pyrH and L-
lacH). Moreover, by changing the concept of enzyme
kinetics, proton-linked MCTs no longer drive equilibrium
reactions. Instead they act unidirectionally and pyr− and L-
lac− become signaling molecules for distinct mitochondrial
and cytosolic enzyme complexes, able to trigger distinct
metabolic signaling pathways. The mitochondrial LDH-
h•MCT1 complex [40] and the postulated lac−-tricarboxylic
acid (TCA)/electron transport chain (ETC) cycle [35] led us
to consider L-lac− and pyr− as catabolic and anabolic sig-
naling molecules, respectively.
Mitochondrial LDH activity was first suggested by
Dianzani in 1951 [41] and later, LDH-h was localized to
mitochondria [42]. Over 30 years later, the mitochondrial
proton-linked MCT1•LDH-h complex was functionally
characterized [40]. The mitochondrial proton-linked
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MCT1•LDH-h complex oxidizes L-lac− to pyr− and trans-
fers pyrH through the inner mitochondrial membrane. From
1961–1990, L. Reed consistently published that pyrH, not
pyr−, is substrate of the alpha-ketoacid dehydrogenase,
pyruvate dehydrogenase (PDH) complex [43, 44]. It is
ironic, that although didactic teaching has set pyr− as the
end product of so-called ‘aerobic’ glycolysis, the
mitochondrial pyr− transporter, required for the transfer of
pyrH into the mitochondria, was not discovered until fairly
recently [45, 46]. Thus, whereas in science the L-lac−-TCA/
ETC cycle was already characterized, the didactic glycolytic
flowchart teaches that the product of cytosolic pyruvate
kinase is pyr− and that pyr− is the substrate of PDH com-
plex [47]. Thus, for generations, we have learned alchemy,
Fig. 2 The ‘sending’ and ‘receiving’ of signals via glucose meta-
bolism. a Glucose, taken up via glucose transporters (GLUTs) and
produced by the breakdown of glycogen (glycogenolysis) is exported
as a signal via GLUTs. In addition, glucose is converted to pyruvate
(pyr−) and lactate (L-lac−) via glycolysis and exported as pyruvic acid
(pyrH) and lactic acid (L-lacH) via the proton-linked monocarboxylate
transporter 4 (MCT4)•phosphoglycerate kinase (PGK) complex [35].
b Pyr− and L-lac- are imported as pyrH and L-lacH into the cell via
the MCT1•carbonic anhydrase II (CAII) complex [35]. A cytosolic
muscle lactate dehydrogenase (LDH-m)•proton donor (PD) complex
converts pyruvate (pyr−) to lactate (L-lac−) and a cytosolic heart LDH
(LDH-m)•proton acceptor (PA) complex converts lactate (L-lac−)
to pyruvate (pyr−). Alternatively, L-lac− is converted to pyr− by
the proton-linked mitochondrial MCT1•LDH-h complex to fuel the
L-lac−-tricarboxylic acid (TCA)/electron transport chain (ETC) cycle
[35]. Pyr− is transported into the mitochondrial matrix via the mito-
chondrial pyr− carrier (MPC) to power the pyr−-TCA cycle [35] tit. A
violet H+ indicates the H+ is part of a proton-coupled reaction. The
blue H+ indicated on the pyrH transferred by the MPC, comes from
the mitochondrial matrix.
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a concept based on faith and not the law of mass
conservation.
Our tentative sorting of glycolytic enzymes is helpful for
the astrocyte-neuron lactate shuttle hypothesis [48]. How-
ever, the concept that L-lac− is food for ‘thoughts’ (memory
consolidation) cannot rationally be followed on basis of well-
established enzyme kinetics, because here, the uptake of L-
lacH is the uptake of a substrate of an anabolic pathway
(gluconeogenesis) [49]. Enzyme kinetics, based on con-
centration-equilibration, predicts that increasing L-lac− is
building block for storage and not for consumption. How-
ever, combining the import and export of monocarboxylic
acids (in sterically separated and distinctly regulated
domains) with the mitochondrial proton-linked MCT1•LDH-
h complex, means that imported L-lac− must be consumed. L-
lac− becomes a substrate for the mitochondrial catabolic
pathway. If we consider that the provision of an energy entity
(H+) predicts the activity of the complex, the activity of
LDH-h complexes depends on the L-lac− concentration.
Thus, L-lac−, generated from either increased glycogenolysis
or increased uptake of L-lacH, accelerates ETC activity.
Given that the inner-complex stability of NADH-H+ is time-
dependent, a relative absence of the substrate of the coupled
enzymatic reaction is signaled by the release of the ‘second
messengers’, NADH and H+. In contrast, LDH-m acts as a
proton acceptor in enzyme complexes. Here pyr− does not
provide the energy entity, H+, instead LDH-m accepts
NADH-H+. Thus, the relative absence of pyr− also predicts
the release of the ‘second messengers’.
Whereas increased uptake of L-lacH enhances the ‘cata-
bolic’ signaling pathways via cytosolic and mitochondrial
LDH-h complexes, increased uptake of pyrH is detected by
‘anabolic’ signaling pathways, via cytosolic LDH-m com-
plexes and the mitochondrial pyr− transporter. The dis-
tinction between pyrH and lacH is made clear in the animal
model of exercise-induced hyperinsulinism. Here, the
proton-linked MCT1 uptake of pyrH, but not L-lacH, trig-
gers insulin release by pancreatic β-cells [22].
Schizophrenia treatments: electroconvulsive
therapy and olanzapine
The brief tour we have taken down the ‘glucose creek’,
together with the exchange of monocarboxylates is suffi-
cient to de-mystify the mysterious mechanism of electro-
convulsive therapy (ECT) for treating schizophrenia [50].
Fear conditioning experiments performed using animal
models of learning [4] and electroshock therapy, first
described in 1756 by Wesley [51], have one thing in
common. They both trigger glycogenolysis. Now, by sim-
ply changing the point of view and considering the biolo-
gical function of glycogen granules as a storage of
metabolic signaling molecules and cross-referencing with
the fact that the scientific field of learning and behavior
acknowledges astrocytic glycogenolysis as a key mechan-
ism. We can de-mystify ECT as a mechanism for the
nonspecific activation of a signaling pathway; astrocytic
glycogenolysis.
Let us consider ECT and sodium-serotonin reuptake
inhibitors (SSRIs). ECT causes upregulation of cell surface
Na+/serotonin symporters in thrombocytes [50]. Thus
SSRIs, by blocking the activity of Na+/serotonin symporter,
act in the diametrical opposite way. There is evidence that
Na+/serotonin symporter activity is linked to the glycogen
storage pool, because SSRIs cause the depletion of glyco-
gen storage in thrombocytes [52]. Furthermore, SSRIs
impair thrombocyte hemostatic responses, with bleeding a
side effect of SSRI medication. Therefore, it is logical to
assume that the depletion of the glycogen pool indicates an
imbalance in the metabolic balancing between anabolic and
catabolic pathways, in favor of catabolic pathways. There is
evidence that SSRIs stimulate astrocytic glycogenolysis
[53, 54]. The increase in astrocytic glycogenolysis is a
signal that can be conveyed to neurons via supply of glu-
cose and a change in the transfer of monocarboxylates i.e.,
the L-lac−/pyr− ratio. As neurons do not have glycogen
stores, they cannot respond to SSRIs by increasing glyco-
gen breakdown. Thus, pharmacological blockage of Na+/
serotonin symporter activity encodes a signal changing the
metabolic balance in astrocytes and neurons in the direction
of catabolic pathways. However, although the astrocytic
signal impacts the stability and glucose consumption of
astrocyte-neuron compartments, SSRIs are only likely to
increase presynaptic glucose consumption. This suggests a
mechanism for the actions of SSRIs in the treatment of
schizophrenia patients [55].
In an organism, the dynamic exchange of the signaling
molecules, glucose, pyrH, and L-lacH, allows certain cells,
such as muscle and brain cells to adapt or to learn from
increased metabolite provision. Pancreatic β-cells partici-
pate in detection and regulation, and other cells such as
adipocytes, act as storage. It is well known that anti-
psychotics, such as olanzapine, have a huge impact on
glucose homeostasis in humans. Lynch and co-workers
determined the transcriptional changes induced by olanza-
pine treatment on genes related to the metabolism of glu-
cose in rats [56]. If we extrapolated the observed mRNA
changes in rat muscle to human astrocytes, pancreatic β-
cells, and adipocytes, then we could infer that the decrease
of mitochondrial Slc16a1 and Ldhb (genes of the
MCT1•LDH-h complex) (Table 1) would decrease mito-
chondrial L-lac− consumption. The decreased L-lac− con-
sumption would then change the cytosolic L-lac−/pyr− ratio,
in favor of L-lac−. Astrocytic glycogenolysis greatly
increases the L-lac-/pyr- ratio [17]. This signal encodes the
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postulated stabilization of the astrocyte-neuron compart-
ment and increases activity of LDH-h complexes. Hereby,
astrocytes and neurons learn to consume more glucose by
stabilizing the astrocyte-neuron compartment and upregu-
lation of GLUTs [30].
We interpret the data of Tadi and co-workers that both
astrocytes and neurons adapt their cell homeostasis to a
higher glucose turnover. This interpretation contrasts with
the astrocyte-neuron lactate shuttle hypothesis, which
focuses on L-lac− as food for hungry neurons. Thus, an
increase in monocarboxylic acid transfer, here interpreted as
astrocyte-neuron communication [39], should entail the
upregulation of neuronal proton-linked MCT2, but not the
upregulation of neuronal GLUTs.
Increases in Gapdh and Ldha (GAPDH•LDH-m com-
plex) and Slc16a3 and Pgk1 (MCT4•PGK complex) would
increase the glycolytic flux in astrocytes and muscles
[56, 57]. The decrease in Hk2 (hexokinase II) in pancreatic
β-cells would result in an impaired detection of glucose,
giving rise to hyperglycemia [58]. The decrease of Slc16a1
and Ldhb would mean less substrate for the catabolic L-lac−-
TCA/ETC cycle. This would shift glucose metabolism
towards the preferentially anabolic pyr−-TCA cycle, which
likely depends on the acidic pH of the mitochondrial matrix
[59] or alternatively, is driven by mitochondrial pyrH/car-
bonic acid antiporter. Together, this shift may be responsible
for the weight gain in olanzapine-treated patients [60]. Cells
not designed for energy storage, would ‘starve’ and switch
to free fatty acids as an energy source, even during hyper-
glycemia [58]. The impact of olanzapine on metabolism was
brilliantly shown by the fact that the switch to fatty acid
metabolism is required for survival [61].
By drawing on a wealth of information taken from bench
to bedside. The presented concept of glucose metabolism
fits well as a unifying hypothesis of schizophrenia and
explains the observed effects of ECT and pharmacological
medication.
Discussion
The review provides a simple, biologically based hypothesis
of schizophrenia. It is sufficient to integrate most aspects of
schizophrenia including treatment with ECT or olanzapine.
We have deliberately focused on the ‘second hit’ of the
astrocytic glycolysis and visited dysregulated glucose
metabolism. We have not looked forward and examined the
signaling pathways activated by biomarker candidates of
schizophrenia, such as tumor necrosis factor-alpha, IL-1β,
and IL-6. However, we have looked back and found that
glucose and glucose metabolites are a common denominator
in the release of these biomarkers.
The presented concept of glucose metabolism is highly
original. All the key points regarding glucose metabolism as
a signaling pathway already published, but interestingly
have not been brought together into one unifying hypoth-
esis. Of course, not all the points highlighted are found in
the common understanding of glucose metabolism and are
therefore sometimes ignored or rejected by the scientific
community. Just suggesting that pyrH, instead of pyr− is the
substrate of the mitochondrial PDH complex [43] and
illustrating membrane-located PGK at the membrane [62],
make this hypothesis unique.
In our discussion of glucose metabolism, we place the
mitochondrial proton-linked MCT1•LDH-h as a pH-
independent complex, feeding the catabolic L-lac−-TCA/
ETC cycle. The mitochondrial location of proton-linked
MCT1 and LDH-h is highly controversial. Neither has a
typical mitochondrial-targeting motif. However, the pre-
sence of such a motif would dictate a mitochondrial location
and thereby, exclude dynamic sorting of LDH-h and proton-
linked MCT1. For example, GAPDH does not possess
nuclear- or mitochondrial-localization motifs, yet it translo-
cates to these compartments under certain cellular conditions
[11, 63]. In fact, topogenic signals and energy requirements
dynamically regulate the localization of the proteins in yeast
[64]. Biological processes are guided by economy; the
saving of time and energy. For example, the exchange of
NADH-H+ for NAD+ acts as a direct feedback mechanism
for the ETC [35]. A direct exchange of mitochondrial LDH-
h-generated NADH-H+ with the end product of the ETC,
NAD+, is more efficient and quicker than recovery of
cytosolic generated NADH-H+ via glycerol-3-phosphate
(G3P) shuttle. In the G3P shuttle, pyr− and G3P have to
diffuse into the mitochondria and dihydroxyacetone-
phosphate has to diffuse back into the cytosol to recover
cytosolic NAD+. In addition, the overall efficiency is
Table 1 List of gene and common protein names and abbreviations.
Gene name Common protein name Abbreviation
in text




Hk2 Hexokinase II None
Ldha Muscle lactate dehydrogenase LDH-m
Ldhb Heart lactate dehydrogenase LDH-h
Pgk1 Phosphoglycerate kinase PGK
Slc16a1 Monocarboxylate transporter 1 MCT1
Slc16a3 Monocarboxylate transporter 4 MCT4
Slc16a7 Monocarboxylate transporter 2 MCT2
Slc9a1 Na+/H+ exchanger 1 None
Slc9a2 Na+/H+ exchanger 2 None
Slc9a3 Na+/H+ exchanger 3 None
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reduced by the fact that mitochondrial G3P dehydrogenase
uses the electron carrier flavin adenine dinucleotide (FAD),
which generates fewer ATP molecules i.e., less energy. In
contrast, time and energy are saved by the LDH-h-driven
exchange of NADH-H+ for NAD+, because L-lac− is sub-
strate of the PDH complex and a carrier of the redox
equivalent of one NADH-H+ We are aware that pyr− was
preferentially sorted into the anabolic pyr−-TCA cycle, but
here we discuss the G3P shuttle in context of catabolism. It
would be of great interest to understand the roles of pyr− and
G3P as regulators of lipid synthesis and the formation of
FAD-H2, perhaps coupled to ETC.
The rationale for connecting enzymes and forming
functional enzymes complexes comes from the tentative 4th
law of thermodynamics [65, 66] and the proton transport
chain hypothesis [35]. The tentative 4th law of thermo-
dynamics was first described in physics and later transferred
to economy and biology. It states ‘a flow of energy is suf-
ficient to form ordered structure’ [65]. The proton transport
chain hypothesis transfers the 4th law of thermodynamics to
biology by using the active H+ as the energy entity that
orders organisms. In biology, glucose and ATP are stores of
energy, like a battery, but the flow of energy is provided by
ions, such as H+ or Na+.
In 1956, Crane described the mechanism of the Na+/glu-
cose symporter [67]. This symporter re-absorbs Na+ and glu-
cose from gut and pre-urine, by using the flow of Na+ (energy)
to transport glucose against a concentration gradient. Thus, the
Na+/glucose symporter produces entropy, a glucose gradient
and the flow of energy drives the direction of the transport. It is
clear that if the intracellular concentration of Na+ were higher
than the extracellular, then the same symporter would export
glucose [68]. However, in biology, in the setting of an
organism, the direction of the Na+/glucose symporter is set to
act unidirectionally. A similar scenario exists for the mito-
chondrial ATP synthase complex. For example, if the pH
gradient driving the synthesis of ATP were flipped, then the-
oretically the mitochondrial ATP synthase complex would
hydrolyze ATP and pump out protons. However, we prefer to
stay within the realms of biology and understand that a flow of
energy, in this case, protons, is sufficient to drive the ATP
synthase complex and the PDH complex. Thus, investigating
isolated enzymes extrudes them from the biological context,
disconnecting them from the flow of energy. Isolated enzymes
in a test tube reversibly catalyze a concentration equilibrium in
a closed system. In contrast, biology describes an open system
where energy and material are free to move, i.e., another type
of system with different rules.
It is quite interesting that ammonia (NH3) or alkalization
of the cell, affects the L-lac−/pyr− ratio in astrocytes, but not
in neurons [59]. From our point of view, the rationale that
quenching the activity of pH-sensitive (astrocytic) mito-
chondrial pyr- transporter is responsible for the effect is
critical. This suggests that the membrane transfer of pyr−
depends on the pH and not on mitochondrial provision of
carbonic acid. This interpretation also suggests that the
activity of neuronal pyr- transporter is virtually nil. On the
other hand, Na+/H+ exchangers are well known to regulate
cellular pH [69] and in line with our thinking, we predict
that these too, transport unidirectionally. The acidifying
Na+/H+ exchanger 1•CAII complex has already been
shown to exist, with CAII enhancing exchanger activity
[70]. It will be interesting to determine if biology is really
simple and that the alkalinizing Na+/H+ exchanger 3
(Slc9a3) [71] forms a complex with PGK.
It might seem strange to develop a hypothesis of schi-
zophrenia, without mentioning dopamine. However, float-
ing down this path we would have to mention the
constitutive activity of G protein-coupled receptors. For
example, the constitutive activity of dopamine-1-like
receptors (D1R and D5R) increases basal cAMP levels. In
contrast, the dopamine-induced effect decreases cAMP
levels. Constitutive D5R activity increased Na
+/H+
exchanger activity, increased cytosolic pH and accelerated
glucose degradation due to increased transcription and
translation of the Na+/K+-ATPase and Na+/H+ exchanger 2
[72]. So what effect does this balance between constitutive
and agonist-induced activity have on cell–cell signaling via
neurotransmitters? How is cell homeostasis regulated by
constitutive G protein-coupled receptor activity through
regulation of glucose metabolism?
Thankfully for scientists, the cell is not just a set of
randomly distributed pieces, but a complex puzzle to be
solved.
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